(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2017 (14.12.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/214014 A1

(51) International Patent Classification:
A61K 31/454 (2006.01) *A61P 35/02* (2006.01)
A61K 31/4545 (2006.01)

(21) International Application Number:
PCT/US2017/035892

(22) International Filing Date:
05 June 2017 (05.06.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/346,344 06 June 2016 (06.06.2016) US

(71) Applicant: **CELGENE CORPORATION** [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US).

(72) Inventors: **CARRANCIO, Soraya**; 5205 Fiore Terrace, Apt. B419, San Diego, CA 92122 (US). **HOLLENBACH, Paul**; 20793 Gleenwood Drive, Castro Valley, CA 94552 (US). **LOPEZ-GIRONA, Antonia**; 8959 January Place, San Diego, CA 92122 (US). **MACBETH, Kyle**; 1356 Stevenson Street, San Francisco, CA 94103 (US). **POURDEHNAD, Michael**; 3972 26th Street, San Francisco, CA 94131 (US). **RAPPLEY, Irit**; 2645 Gobat Avenue, San Diego, CA 92122 (US).

(74) Agent: **BHUMRALKAR, Megha** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: TREATMENT OF A HEMATOLOGIC MALIGNANCY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE




FIG. 1

(57) Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

[Continued on next page]

WO 2017/214014 A1

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*